DAPAGLIFLOZIN 10mg. IP + METFORMIN 500mg. IP

An antihyperglycemic drug that improves glycemic control in adults with type 2 diabetes mellitus. A beneficial therapeutic therapy for patients with type 2 diabetes and improves postprandial blood glucose. (Plosker, 2012) An effective drug in individuals both early and late in the course of diabetes. (Anders, 2014) A well-tolerated and effective agent in reducing glycated hemoglobin, fasting plasma glucose, and weight in patients with type 2 diabetes. (R R Henry, 2012) Improves glycemic parameters in patients with type 2 diabetes. (Vivian, 2015) Represents a novel approach to the management of type 2 diabetes mellitus. (Niren K Shah, 2012) Possesses blood pressure-lowering properties and leads to improvement in HbA1C measurements.(Michael A Weber, 2016) Reduces weight and produces less hypoglycemia than glipizide in type 2 diabetes patients who are inadequately controlled with metformin. (M Nauck, 2013) A well-tolerated medicine associated with sustained glycemic efficacy and greater reductions in body weight and systolic blood pressure than glipizide. (S Del Prato, 2015) A safe and effective drug as monotherapy or as an add-on to insulin or oral antidiabetic agents in type 2 diabetes patients. (Paola Fioretto, 2015)